CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
Bromfenacdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01535443
NCT01535443Phase 1Completed
CompareCT.gov

Fase 1 Study to Evaluate the Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.

Laboratorios Sophia S.A de C.V.·interventional·Posted Feb 17, 2012·Updated Oct 16, 2019

In Brief

A Phase 1 clinical trial evaluating Bromfenac for Inflammation and Cataract. Completed, enrolled 35 participants across 1 site.

Detailed Summary

Study to evaluate the safety and tolerability of PRO-155 Ophthalmic Solution 0.09 % in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInflammation, Cataract
CountriesMexico
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 17, 2012
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.4 years ago

Interventions

Bromfenacdrug

Drug: Bromfenac Other names: PRO-155